Northern Ireland Clinical Trials Unit

SERIOUS ADVERSE EVENT (SAE) REPORT FORM

Please submit the SAE Report Form within 24hours of becoming aware of the event to the Northern Ireland Clinical Trials Unit by Email: clinicaltrials@nictu.hscni.net

You are not required to enter the SAE form onto the MACRO EDC database.

This will be completed by staff at the Northern Ireland Clinical Trials Unit

REPORT DETA	AILS												
Type of Repor	t: Initi	al [Follow	Up, Num	her								
TRIAL DETAIL		ui .	1011011	op, ivair									
Protocol Acror	nym: MARCH		Protoc	ol No:	20131DMc	A-AS	Eudi	aCT No	: 2021-0037	2021-003763-94			
SITE DETAILS	L				ı								
Site Number:			Site Na	me:									
PATIENT DET	AILS		L		l								
Participant Stu	ıdy Number:		Patient	: Initials:	D	ate of Bi	rth: DD MI	/I YYYY	Sex: □ N	∕lale □	Female		
EVENT DETA	ILS				J J								
Date of Onset	of Serious Advers	e Event:	DD MN	1 YYYY									
Date Site Beca	me Aware of the	Event:	DD MN	1 YYYY									
Seriousness (V	Vhy was the Event		 □ Is life-threatening □ Requires hospitalisation or prolongation of existing hospitalisation □ Results in persistent or significant disability or incapacity □ Consists of a congenital anomaly or birth defect 										
If Other, pleas	e specify:												
If Resulted in L	Death, Date of D	eath:	DD MN	DD MM YYYY									
,	Cause of												
	cause of t	Deutii.											
Main Diagnosi	s/Symptom (SAE	Term)						Severity/Grade ¹ SAE Status ²			tesolved		
										DD MI	VI YYYY		
¹Severity/Grade	: 1 = Mild (Grade 1) 2 = Mo	oderate (Grad	rate (Grade 2) 3 = Severe (Grade 3)				4 = Life Threatening (Grade 4) 5 = Death (Grade 5)					
² SAE Status:	1 = Resolved		•	yed with Sequelae 3 = Unresolved				4 = Fatal					
Please indicate	e which treatment	group th	e natient is	in:									
Carbocisteine			onic Saline		Carbocist Hyperton				sual Airway Cle lanagement				
Trial Mucoacti	ive		Causality ¹	Expec	tedness ²		Please provide date of approved Reference Safety Information used Date (if applicable)			nce			
Carbocisteine							DD MM Y		,				
Hypertonic Sal	ine						DD MM Y	YYY					
¹Causality:	1 = Not related Indicate the extent	2 = Unli		= Possibly			5 = Definit	ely	6 = N/A				
	maicate the extent	to willCil t	ne event ilidy	DE LEIGIE	a to the study (ıı ug.							
² Expectedness:	PExpectedness: 1 = Expected 2 = Unexpected 3 = N/A If 'Causality' is graded as Possibly, Probably or Definitely related please indicate whether the event is 1 = Expected or 2 = Unexpected as per the Reference Safety Information. If 'Causality' is graded as Not Related or Unlikely to be related, please record 'Expectedness' as 3 = N/A.										ase record		
If the event is related and unexpected it is a Suspected Unexpected Serious Adverse Reaction (SUSAR) and requires expedited reporting in collaboration with the NICTU and within regulatory timelines.													

ASSESSME	NT OF EVENT COMPLETED BY (This section n	ust be completed by a medically q	ualified investiga	tor)
Name:	Signature	:	Date Assessed:	DD MM YYYY

Doc No.: TM03_LB01

fast Health & Social Care Trust	Northern Ireland Clinical Trials Uni
ESCRIPTION OF EVENT:	
rovide a medical description of the event including, any treatment given on tinue on separate sheet if necessary.	n and any relevant tests (e.g. lab tests) carried out.

Trial Mucoactive Date of First		Date of Dose at		Units ¹	Route ²	Action	Date Trial Drug	
	Administration	Most Recent	Most Recent			Taken with	Stopped	
		Administration	Administration			Trial Drug ³	(if applicable)	
Carbocisteine	DD MM YYYY	DD MM YYYY					DD MM YYYY	
Hypertonic Saline	DD MM YYYY	DD MM YYYY					DD MM YYYY	

¹Units:	1 = Milligra	n (mg) 2 = Microgr		2 = Microgram (μg) 3 = Gram (g)		4 = Millilitre (ml)	5 = Tubs/tubes	6 = Puffs/inhalers			
Offics.	7 = Drops		8 = Spray(s)		9 = Bottles	10 = Packs	11 = International U	nit (IU)	12 = Other		
²Route:	1 = Enteral	2 = Nebi	ulised 3 = Oral			4 = Other					
³ Action Taken:	1 = None	2 = Dose	Reduced 3 = Treatment Delayed			4 = Treatment Rec	ment Stopped	6 = Other			

	7 = Drops	8 = Spray(s)	9 = Bottles	10 = Packs	11 = International Unit (IU)		12 = Other				
² Route:	1 = Enteral	2 = Nebulised 3 = Oral 4			4 = Other							
³ Action Taken:	1 = None	2 = Dose Reduced	3 = Trea	tment Delayed	4 = Treatment Rec	duced & Delayed	5 = Treat	tment Stopped 6 = Oth				
				•				•				
DETAILS OF T	RIAL MUCO	ACTIVE REDUCTIO	N AND/O	R DELAY OR O	OTHER ACTION TA	KEN:						
If trial mucoad	ctive was re	duced and/or delay	ed, spec	ify length of d	elay and how mu	ch dose was reduce	d by.					
If 'Other' action	If 'Other' action was taken, please provide details below.											

TREATMENT GIVEN FOR MANAGEMENT OF THE SERIOUS A	DVERSE EVENT (SAE)							
Mostly and and all and an arranged front and a transfer for the second 2								

TREATMENT GIVEN FO	OR MANAGEMENT OF THE	SERIOUS A	ADVERSE I	EVENT (SAE)						
Was the patient given a	ny medication to treat the eve	ent?	☐ Yes ☐ No							
Drug Name	ug Name Total Daily Dose Units ¹					oing	Stop Date			
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	
				DD MM YYYY		Yes		No	DD MM YYYY	

Doc No.: TM03_LB01 SAE Form MARCH_1.0 Final_31/08/2021

Belfast Health & Social Care Trust

Northern Ireland Clinical Trials Unit

CONCOMITA	ANT MEDICAT	IONS									
Was the patie	ent on any conc	omitant medications?		□ Y	es 🗌 No						
Drug Name		Total Daily Dose	Units1	Route	2 Start Date	Ong	oing			Stop Da	ite
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
							Yes		No	DD MM	YYYY
						$+\overline{-}$	Yes		No	DD MM	
							Yes		No	DDMM	
				<u> </u>					-		
¹Units:	1 = Milligram (r		3 = Gram (g	g)	4 = Millilitre (ml)		ubs/tubes		: . / ! !		ffs/inhalers
² Route:	7 = Drops 1 = IV	8 = Spray(s) 2 = Oral	9 = Bottles 3 = Subcuta	neous	10 = Packs 4 = Other	11 =	Internatio	onai Un	it (IU)	12 = 0	tner
Noute.	1-10	2 - 0101	3 - Subcutt	incous	4 - Other						
MEDICAL HI	STORY										
Any relevant	medical history	/concurrent conditions?	? 🗆	Yes [No						
OTHED DELE	VANT INFORM	AATION2									
	evant informati		□ No								
		1									
ADDITIONA	L INFORMATIO	ON									
Was trial mu	coactive taken a	s per protocol?			Yes 🗆	No			N/A		
Was the pation	ent withdrawn f	rom the study because	of the event?		Yes	No					
REPORTERS	DETAILS										
Name:			Signature	:				Date	e:	DD MM	YYYY
FOR CTU USE ONLY			FOR CLIN	IICAL R	EVIEWER USE OF	NLY					
Date Receive		DD MM YYYY	Event:		□ SAE	-		SAR			SUSAR
Form Receive	ed By:		Comment	s:							
SAE Event No											
If Event was	a SUSAR	•	Preferred	Term							
Date Reporte	d to Sponsor:	DD MM YYYY	Body Syst	em Org	an Class						
Date Reporte	d to MHRA:	DD MM YYYY	Date Revi	ewed:		DDI	VIM YYYY	/			
Date Reporte	d to Ethics:	DD MM YYYY	Reviewer	Signatu	re:						

Doc No.: TM03_LB01